Skip to Content

Qiagen N.V.

Securities Class Action

  • Date:
  • 5/15/2026
  • Company Name:
  • Qiagen N.V.
  • Stock Symbol:
  • QGEN
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) on behalf of Qiagen stockholders. Our investigation concerns whether Qiagen has violated the federal securities laws and/or engaged in other unlawful business practices.

On February 5, 2026, Qiagen reported its financial results for the fourth quarter of 2025 and stated that its QuantiFERON product was expected to accelerate to achieve “between 6% and 7% growth” in 2026.

 

On April 27, 2026, Qiagen announced preliminary financial results for the first quarter of 2026. Among other disclosures, the Company reported that net sales declined approximately 1% on a constant exchange rate (“CER”) basis and that sales of its QuantiFERON product declined approximately 5% CER. Following this announcement, the price of Qiagen shares fell by $4.07 per share, or approximately 11%, declining from $38.09 per share on April 27, 2026 to close at $34.02 per share on April 28, 2026.

If you purchased or otherwise acquired Qiagen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Qiagen N.V. . BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: